MAGGIC Heart Failure Risk Score
Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk calculator. Predicts 1- and 3-year all-cause mortality in patients with heart failure (both HFrEF and HFpEF).
Score interpretation
→ MAGGIC Low Risk (0–12): <5% 1-year mortality. Continue optimised GDMT; patient education; HF nurse follow-up; telemonitoring; annual echocardiogram.
→ MAGGIC Intermediate Risk (13–20): 5–15% 1-year mortality. Optimise GDMT (ARNI, SGLT2i, MRA); HF clinic; palliative care discussion if NYHA III–IV; consider ICD/CRT; dietitian; salt restriction.
→ MAGGIC High Risk (>20): >15% 1-year mortality. Advanced HF therapies: LVAD, transplant listing, or palliative pathway. Inotrope consideration; goals-of-care discussion; specialist palliative HF team; prognostic counselling.
Interpretation bands for the MAGGIC Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Bisoprolol (Heart Failure in Elderly) · Selective beta-1 blocker
- Carvedilol · Beta-Blocker / HFrEF
- Sotalol hydrochloride · Class III antiarrhythmic + non-selective β-blocker
- Labetalol (IV — Hypertensive Emergency) · Combined Alpha-1 and Beta-Adrenergic Blocker
- Metoprolol (IV/Oral — Cardiology) · Beta-Blocker
- Candesartan (HFrEF / ACEi Intolerance) · ARB / HFrEF
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.